MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 326655 | Name: Ornipressin Acetate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ornipressin is a vasoconstrictor, haemostatic and renal agent. Ornipressin (Por 8) is also an efficient alternative to counteract hypotension during combined general/epidural anesthesia. Ornipressin plus dopamine can be a useful therapeutic option in patients with HRS type 1, especially as bridge to liver transplantation.

Chemical Structure

Ornipressin Acetate
Ornipressin Acetate
CAS#914453-98-8 (acetate)

Theoretical Analysis

MedKoo Cat#: 326655

Name: Ornipressin Acetate

CAS#: 914453-98-8 (acetate)

Chemical Formula: C47H67N13O14S2

Exact Mass: 0.0000

Molecular Weight: 1102.25

Elemental Analysis: C, 51.21; H, 6.13; N, 16.52; O, 20.32; S, 5.82

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 Weeks
10mg USD 550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
914453-98-8 (acetate) 3397-23-7 (free base)
Synonym
Ornipressin Acetate; POR 8. 8-Ornithinevasopressin; Vasopressin, 8-L-ornithine-.
IUPAC/Chemical Name
H-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Orn-Gly-NH2 (Disulfide bond)
InChi Key
AYJSELDHDXYDKX-HPILINOVSA-N
InChi Code
InChI=1S/C45H63N13O12S2.C2H4O2/c46-16-4-8-28(39(64)51-21-37(50)62)53-44(69)34-9-5-17-58(34)45(70)33-23-72-71-22-27(47)38(63)54-30(19-25-10-12-26(59)13-11-25)42(67)55-31(18-24-6-2-1-3-7-24)41(66)52-29(14-15-35(48)60)40(65)56-32(20-36(49)61)43(68)57-33;1-2(3)4/h1-3,6-7,10-13,27-34,59H,4-5,8-9,14-23,46-47H2,(H2,48,60)(H2,49,61)(H2,50,62)(H,51,64)(H,52,66)(H,53,69)(H,54,63)(H,55,67)(H,56,65)(H,57,68);1H3,(H,3,4)/t27-,28-,29-,30-,31-,32-,33-,34-;/m0./s1
SMILES Code
NCCC[C@@H](C(NCC(N)=O)=O)NC([C@@H]1CCCN1C([C@@H]2CSSC[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N2)=O)CC(N)=O)=O)CCC(N)=O)=O)Cc3ccccc3)=O)Cc4ccc(O)cc4)=O)N)=O)=O.CC(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Ornipressin is a vasoconstrictor, haemostatic and renal agent.
In vitro activity:
TBD
In vivo activity:
TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 1,102.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
TBD
In vitro protocol:
TBD
In vivo protocol:
TBD
1: Ngichabe S, Obura T, Stones W. Intravenous tranexamic acid as an adjunct haemostat to ornipressin during open myomectomy. A randomized double blind placebo controlled trial. Ann Surg Innov Res. 2015 Oct 31;9:10. doi: 10.1186/s13022-015-0017-y. eCollection 2015. PubMed PMID: 26568770; PubMed Central PMCID: PMC4644022. 2: Henn EW, Nondabula T, Juul L. Effect of vaginal infiltration with ornipressin or saline on intraoperative blood loss during vaginal prolapse surgery: a randomised controlled trial. Int Urogynecol J. 2016 Mar;27(3):407-12. doi: 10.1007/s00192-015-2821-7. Epub 2015 Aug 21. PubMed PMID: 26294207. 3: Tüller C, Tüller D, Tamm M, Brutsche MH. Hemodynamic effects of endobronchial application of ornipressin versus terlipressin. Respiration. 2004 Jul-Aug;71(4):397-401. PubMed PMID: 15316215. 4: De Kock M, Laterre PF, Andruetto P, Vanderessen L, Dekrom S, Vanderick B, Lavand'homme P. Ornipressin (Por 8): An efficient alternative to counteract hypotension during combined general/epidural anesthesia. Anesth Analg. 2000 Jun;90(6):1301-7. PubMed PMID: 10825311. 5: Gülberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology. 1999 Oct;30(4):870-5. PubMed PMID: 10498636. 6: Gülberg V, Luppa P, Pauletzki J, Paumgartner G, Gerbes AL. [Successful conservative therapy of hepatorenal syndrome with vasopressin-1-receptor antagonist ornipressin]. Z Gastroenterol. 1998 Dec;36(12):1053-8. German. PubMed PMID: 10025057. 7: Kam PC, Tay TM. The pharmacology of ornipressin (POR-8): a local vasoconstrictor used in surgery. Eur J Anaesthesiol. 1998 Mar;15(2):133-9. Review. PubMed PMID: 9587717. 8: Guevara M, Ginès P, Fernández-Esparrach G, Sort P, Salmerón JM, Jiménez W, Arroyo V, Rodés J. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology. 1998 Jan;27(1):35-41. PubMed PMID: 9425914. 9: Giostra E, Ruedin P, Cunningham M, Mentha G, Favre H, Jolliet P, Chevrolet JC. Sustained effects of ornipressin in hepatorenal syndrome. J Hepatol. 1995 Jan;22(1):120-1. PubMed PMID: 7751581. 10: Fruhstorfer H, Heisler M. Dose-response relation of ornipressin with regard to vasoconstriction in human skin. Br J Anaesth. 1994 Aug;73(2):220-4. PubMed PMID: 7917739. 11: Veit S. [The effect of nitroglycerin on ornipressin (POR 8)-induced systemic and cardiovascular circulatory changes. An animal experimental study]. Anasthesiol Intensivmed Notfallmed Schmerzther. 1994 Apr;29(2):108-14. German. PubMed PMID: 8199279. 12: Evrard P, Ruedin P, Installé E, Suter PM. Low-dose ornipressin improves renal function in the hepatorenal syndrome. Crit Care Med. 1994 Feb;22(2):363-6. PubMed PMID: 8306699. 13: Veit S, Poethko C, Heidelmeyer CF, Brückner JB. [Ornipressin (POR 8)--effect on coronary blood circulation and the peripheral circulation. An animal experimental study]. Anaesthesist. 1993 Sep;42(9):597-604. German. PubMed PMID: 8214531. 14: Veit S, Müser HG, Böttcher E, Brückner JB. [Signs of a severe myocardial ischemia following peritonsillar infiltration with ornipressin (POR 8)]. Anaesthesist. 1993 May;42(5):320-3. German. PubMed PMID: 8317691. 15: Hemprich A, Niemeyer K, Wöffen H, Hemprich A. [Clinical studies on the influence of Ornipressin (POR 8) on the cardiovascular system in general anesthesia]. Dtsch Zahnarztl Z. 1992 Jan;47(1):48-50. German. PubMed PMID: 1611979. 16: Lenz K, Hörtnagl H, Druml W, Reither H, Schmid R, Schneeweiss B, Laggner A, Grimm G, Gerbes AL. Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology. 1991 Oct;101(4):1060-7. PubMed PMID: 1832407. 17: Buck RH, Cholewinski M, Maxl F. Animal test or chromatography? Validated high-performance liquid chromatographic assay as an alternative to the biological assay for ornipressin. J Chromatogr. 1991 Jul 12;548(1-2):335-41. PubMed PMID: 1939432. 18: Chiarini L, Cantoni E, Bettelli G, Mattioli AV, Cappello C. [The adverse effects induced by ornipressin during oral and maxillofacial surgical interventions under general anesthesia]. Minerva Stomatol. 1991 Jan-Feb;40(1-2):77-9. Italian. PubMed PMID: 2041535. 19: Marsch SC, Schaefer HG. Pronounced bradycardia after application of POR-8 (Ornipressin) under total intravenous anesthesia with propofol. Acta Anaesthesiol Scand. 1990 Aug;34(6):514. Erratum in: Acta Anaesthesiol Scand 1991 Jul;35(5):463. PubMed PMID: 2239127. 20: Fruhstorfer H, Nolte H, Ziegenhagel U. [Cutaneous blood flow following subcutaneous infiltration of lidocaine with and without the addition of adrenaline or ornipressin]. Reg Anaesth. 1990 Jun;13(4):97-100. German. PubMed PMID: 2374837.

View History

NSC-80467

NSC-80467